Three Sixty

3Sixty Biopharmaceuticals is a South African pharmaceutical and biotechnology company focused on addressing unmet medical needs through its 'Ubuntu Medicine' strategy. A subsidiary of the 3Sixty Global Solutions Group, the company operates a diverse portfolio that includes a specialized nuclear medicine division and a clinical research pipeline of small molecules, peptides, and isotopes. Its lead programs utilize Rhenium-188 isotopes for the treatment of unresectable hepatocellular carcinoma, painful bone metastases, and joint inflammation in conditions like rheumatoid arthritis. 3Sixty Biopharmaceuticals maintains a fully integrated commercialization team and centers of excellence to advance precision medicine and diagnostics across the African continent and globally.